Fusion Pharmaceuticals (FUSN) is advancing a candidate which it acquired in February of 2023. It was acquired as an ongoing phase 2 study, known as the TATCIST trial. This is evaluating the use of FPI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback